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ABSTRAK 
Objektif 
Tujuan kajian ini adalah untuk menilai keberkesanan penggunaan satu 
dos magnesium sulfat nebulisasi bercampur dengan salbutamol untuk merehatkan otot 
licin saluran nafas, dan seterusnya membuka saluran pernafasan dalam rawatan 
penyakit lelah berbanding dengan penggunaan salbutamol sahaja. Selepas itu kami 
juga memerhati sebarang penggurangan yang ketara dalam jumlah tempoh rawatan di 
antara dua kumpulan kajian. 
 
Kaedah Kajian 
Ini adalah satu kajian “double blinded, randomised controlled trial”, yang dijalankan di 
Jabatan Kecemasan di Hospital Universiti Sains Malaysia, Kelantan bermula dari 1 
Oktober 2013 sehingga 1 Oktober 2014. Kami mendaftarkan seramai 120 pesakit yang 
mengalami serangan lelah pada tahap sederhana, semua pesakit kemudian secara 
rawak dibahagikan kepada dua kumpulan melalui teknik “block randomization”. 
Kumpulan A (n = 60) diberi ubat sedut dengan salbutamol sahaja (5mg), Kumpulan B 
(n = 60) diberi ubat sedut campuran magnesium sulfat isotonik (7.5% w / v) dengan 
salbutamol (5mg). Tekanan darah, kadar nadi, kadar pernafasan, ketepuan oksigen 
dan kadar aliran puncak ekspirasi (PEFR) dari setiap pesakit diukur pada permulaan 
kajian dan pada 20 minit selepas rawatan. Jumlah tempoh rawatan bermula dari waktu 
pendaftaran sehingga pencapaian PEFR > 80% yang diramalkan telah dicatatkan. 
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Keputusan 
60 pesakit yang telah dibahagikan kepada dua kumpulan kajian mempunyai ciri-ciri 
asas demografi dan klinik yang setanding. Pada masa 20 minit selepas rawatan diberi, 
kumpulan A dan kumpulan B menunjukkan peningkatan statistik yang ketara dalam 
PEFR (100 ± 61 L / min dan 87 ± 42 L / min masing-masing, p <0.001). Kumpulan B 
menunjukkan pengurangan ketara kadar pernafasan dan peningkatan dalam ketepuan 
oksigen min (p <0.001). Walau bagaimanapun, tidak terdapat perbezaan statistik yang 
ketara dalam peningkatan PEFR dan pengurangan jumlah tempoh rawatan di antara 
dua kumpulan kajian ini. Kami tidak melihat sebarang kesan sampingan dari rawatan 
yang diberikan dalam sepanjang kajian ini. 
 
 
Kesimpulan 
Kesimpulannya, penggunaan MgSO4  sebagai ubat pembantu 
kepada salbutamol nebulisasi pesakit lelah tahap sederhana tidak menunjukkan apa-
apa kelebihan dalam kesan terapeutiknya jika berbanding 
dengan salbutamol sahaja. Walau bagaimanapun, paired t-test dilakukan pada pesakit 
dalam kumpulan B MgSO4 menunjukkan kesan positif dalam membantu pembukaan 
saluran pernafasan, statistik mempamerkan kemampuan MgSO4 untuk menurunkan 
kadar pernafasan dan meningkatkan ketepuan oksigen yang ketara. Dalam 
kajian masa depan, kita mencadangkan terlebih dahulu menjalankan satu kajian 
perintis untuk menunjukan mengetahui “dose-response 
relationship magnesium sulfat dalam rawatan penyakit lelah akut, sebelum satu lagi 
kajian berbagai pusat yang lebih besar dijalankan. 
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ABSTRACT 
Objective 
The aim of this study is to evaluate the efficacy of single dose nebulized magnesium 
sulfate in augmenting bronchodilatory effect of salbutamol in acute asthma as compare 
to salbutamol alone. In addition, we also observe for any significant reduction in total 
treatment duration in this two study groups.  
 
Methodology 
This was a double blinded, randomized controlled trial, conducted in Emergency 
Department of Hospital Universiti Sains Malaysia, Kelantan between 1st October 2013 
and 1st October 2014. We enrolled a total of 120 patients with moderate acute 
exacerbation of bronchial asthma, all the patients were then randomized into two 
groups via block randomization technique. Group A (n=60) nebulized with salbutamol 
only (5mg), Group B (n=60) nebulized with isotonic magnesium sulfate (7.5% w/v) plus 
salbutamol (5mg). Blood pressure, pulse rate, respiratory rate, oxygen saturation and 
peak expiratory flow rate (PEFR) of each patient were measured at baseline and at 20 
minutes post-treatment. Total duration of treatment started from time of enrollment until 
achievement of predicted PEFR > 80% was recorded. 
 
Results 
The 60 patients enrolled in each treatment arm had comparable baseline demographic 
and clinical characteristics. At 20 minutes post-treatment, Group A and Group B 
xiv 
 
showed statistically significant improvement in PEFR (100±61 L/min and 87±42 L/min 
respectively, p value <0.001). Group B showed significant reduction of mean 
respiratory rate and improvement in mean oxygen saturation (p value <0.001). 
However, there were no statistically significant differences in means improvement of 
PEFR and reduction of total duration of treatment between two groups. We did not 
observe any adverse effect from treatment at all time.  
 
Conclusion  
In conclusion, the use of MgSO4 as an adjuvant to salbutamol nebulization in moderate 
AEBA patient does not show any superiority in their therapeutic effect in comparing to 
salbutamol alone. However, paired t-test done on group B population has shown the 
feasible bronchodilatory property of MgSO4, it is able to bring about a statistically 
significant decrease in respiratory rate and improvement in oxygen saturation. In future 
study, we suggest a pilot study to be conducted to establish the dose-response 
relationship of magnesium sulphate in the treatment of acute asthma before a larger, 
multicentre trial is proposed.  
 
 
 
USING ISOTONIC MAGNESIUM SULFATE NEBULIZATION AS AN ADJUVANT 
TREAMENT FOR MODERATE ACUTE EXACERBATION OF BRONCHIAL ASTHMA 
(AEBA) IN ADULT COMPARING WITH SALBUTAMOL ALONE: A DOUBLE BLINDED, 
RANDOMISED CONTROL TRIAL 
 
Dr Liew Ket Keong 
Mmed Emergency Medicine 
 
Department of Emergency Medicine 
School of Medical Sciences, University Sains Malaysia 
Health Campus, 16150 Kelantan Malaysia 
 
 Introduction: Bronchial asthma is a major respiratory disease worldwide. An 
estimated of 300 million individuals all over the world of all different ages have bronchial 
asthma. Exacerbation of bronchial asthma frequently presented with progressive worsening 
of shortness of breath associated with wheezing, cough or chest tightness. Magnesium 
sulfate (MgSO4) is a new agent that has been recommended as an additional treatment for 
AEBA since early of 21st century. Its intravenous use in severe and life threatening AEBA 
has been proven to reduce hospital admission rates. However its use as a nebulizer in the 
treatment of AEBA is still lack of strong evidence for recommendation.  
 
 Objectives: The aim of this study is to evaluate the efficacy of single dose nebulized 
magnesium sulfate in augmenting bronchodilatory effect of salbutamol in acute asthma as 
compare to salbutamol alone. In addition, we also observe for any significant reduction in 
total treatment duration in this two study groups. 
 
Patients and Methods: This was a double blinded, randomized controlled trial, 
conducted in Emergency Department of Hospital Universiti Sains Malaysia, Kelantan 
between 1st October 2013 and 1st October 2014. We enrolled a total of 120 patients with 
moderate acute exacerbation of bronchial asthma, all the patients were then randomized into 
two groups via block randomization technique. Group A (n=60) nebulized with salbutamol 
only (5mg), Group B (n=60) nebulized with isotonic magnesium sulfate (7.5% w/v) plus 
salbutamol (5mg). Blood pressure, pulse rate, respiratory rate, oxygen saturation and peak 
expiratory flow rate (PEFR) of each patient were measured at baseline and at 20 minutes 
post-treatment. Total duration of treatment started from time of enrollment until achievement 
of predicted PEFR > 80% was recorded. 
 
Results: The 60 patients enrolled in each treatment arm had comparable baseline 
demographic and clinical characteristics. At 20 minutes post-treatment, Group A and Group 
B showed statistically significant improvement in PEFR (100±61 L/min and 87±42 L/min 
respectively, p value <0.001). Group B showed significant reduction of mean respiratory rate 
and improvement in mean oxygen saturation (p value <0.001). However, there were no 
statistically significant differences in means improvement of PEFR and reduction of total 
duration of treatment between two groups. We did not observe any adverse effect from 
treatment at all time.  
 
Conclusion: In conclusion, the use of MgSO4 as an adjuvant to salbutamol 
nebulization in moderate AEBA patient does not show any superiority in their therapeutic 
effect in comparing to salbutamol alone. However, paired t-test done on group B population 
has shown the feasible bronchodilatory property of MgSO4, it is able to bring about a 
statistically significant decrease in respiratory rate and improvement in oxygen saturation. In 
future study, we suggest a pilot study to be conducted to establish the dose-response 
relationship of magnesium sulphate in the treatment of acute asthma before a larger, 
multicentre trial is proposed.  
Dr Shaik Farid Abdul Wahab: Supervisor 
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1.0 INTRODUCTION 
 
1.1 Background of the study 
Bronchial asthma is a major respiratory disease worldwide. An estimated of 300 
million individuals all over the world of all different ages have bronchial asthma. The 
global prevalence of bronchial asthma is ranging from 1% to 18% of total disease 
burden (Masoli et al, 2004). In Malaysia, asthma is one of the commonest problems 
treated in the emergency department. The prevalence of bronchial asthma in adult in 
Malaysia was estimated to be 4.5% (Ministry of Health, 2006). 
 
Patients who suffer from bronchial asthma, their symptoms can be well 
controlled with medications or it also can deteriorate at any time if any process of 
airway inflammation causing bronchoconstriction, which is referred to as acute 
exacerbation of bronchial asthma (AEBA). AEBA range in severity from mild to life 
threatening, where most of the time warrant visit to clinics or emergency departments 
for acute treatment via nebulization. 
 
Exacerbation of bronchial asthma frequently presented with progressive 
worsening of shortness of breath associated with wheezing, cough or chest tightness. 
The primary treatment for mild AEBA often required only β2-agonist therapy via 
metered-dose inhaler (MDI). However, moderate to severe exacerbations of bronchial 
asthma mostly required repetitive administration of β2-agonist via nebulizer, early 
introduction of glucocorticosteroids, and oxygen supplements in emergency 
department. 
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During moderate and severe AEBA, often β2-agonist e.g. salbutamol alone is 
not enough to relieve bronchospasm. For this reason, researchers had discovered 
variety of additional agents to alleviate the AEBA symptoms. Ipratropium bromide an 
anticholinergic agent (Rodrigo et al.,2000) has been used as an adjuvant to salbutamol 
in the treatment of AEBA, inhaled glococorticosteroids (Rodrigo et al., 1998) which has 
been proven in their anti-inflammatory effect during an exacerbation. Theophylline is 
another potential but less favorable treatment for AEBA, because evidence has 
showed their narrow therapeutic index that possible harmful to the patient in acute 
exacerbations condition (Parameswaran et al., 2012). Intravenous β2-agonist such as 
salbutamol and terbutaline are reserved for patient with life threatening AEBA (Travers 
et al., 2004). By looking back to the agents mention above, choices of agents in the 
treatment for moderate AEBA are limited. Therefore research for new agents for acute 
management in AEBA is encouraging.  
 
 Magnesium sulfate (MgSO4) is a new agent that has been recommended as an 
additional treatment for AEBA since early of 21st century. Its intravenous use for severe 
life threatening AEBA has been proven to reduce hospital admission rates in certain 
patient. (Rowe et al., 2000). Global Initiative for Asthma (GINA) also recommended 
magnesium sulfate as an adjuvant to salbutamol nebulization in view of its benefits in 
improving pulmonary function and likewise reduces the rate of hospital admissions. 
(Evidence A) (Blitz et al., 2005). 
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1.2 Justification of the study 
By understanding the pathophysiology of acute exacerbation of bronchial 
asthma, various treatment agents have evolved. Traditionally, repeated doses of β2-
agonist nebulization had been the common practice in the treatment of AEBA. As time 
goes by, new evidence has evolved. Anticholinergic agents together with β2-agonist in 
nebulization for children and adults have been proven to reduce the risk of hospital 
admission by 49%. (Plotnick et al., 2000; Stoodley et al., 1999 and Rodrigo et al., 
2000). In addition, Rowe et al, 2007 has also recommended the use of corticosteroid in 
the treatment of AEBA to reduce the risk of relapse.  
 
 Study by Fischl et al. in 1981 showed that, about 41% of AEBA patients in his 
study population had been hospitalized and experienced relapsed. Relapse and 
hospitalization of AEBA patient can be reduced or avoided if more bronchodilatory 
agents have been developed. 
  
 Since the last decade, Magnesium sulfate (MgSO4) has gained some popularity 
as adjunct therapy in the management of AEBA. This agent is easy to use, safe, and 
inexpensive. In North America, intravenous dose of 2g to be given in 20 minutes 
infusion for severe AEBA had been widely accepted by their emergency physician 
(Rowe et al., 2000). Besides, intravenous MgSO4 therapy for severe life threatening 
AEBA has also been recommended in the asthma management guidelines (British 
Thoracic Society, 2011). 
 
 Apart from this, numerous studies have been published worldwide regarding the 
efficacy of nebulized MgSO4 in AEBA. However, there were different outcomes from 
these studies. The reasons for diverse outcomes mainly are due to small number of 
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study population and diversity in study design with different MgSO4 concentration being 
used in the studies. 
 
We are conducting this trial in our center by obtaining a larger sample 
population size; we wish to elicit the significant of mean difference improvement of 
pulmonary function in nebulization MgSO4 with salbutamol group compare with 
salbutamol group alone. At the same time, we would like to observe for any significant 
improvement in time of discharge in these two groups of patient. In future, we hope this 
study may contribute in the evidence pools of efficacy of nebulization MgSO4 in the 
management of AEBA. 
 
 We have chosen patients with moderate AEBA as the group of interest in our 
study. Patient with mild AEBA symptoms can resolve easily with MDI salbutamol at 
home. On the other hand, patient with severe AEBA need to be treated in critical care 
area with more intensive therapy. Besides research has shown the efficacy of IV 
MgSO4 in the treatment for severe AEBA, this therapy has been adopted in most of the 
guideline in the treatment of AEBA. Therefore, patient with moderate AEBA is the most 
suitable group in our study. 
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2.0 LITERATURE  REVIEW 
2.1 Introduction to Bronchial Asthma 
Asthma is a chronic inflammatory disorder of the airways in which many cells 
and cellular elements play a role. It is characterized by recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing. During exacerbation of asthma, it is 
associated with widespread but variable airflow obstruction that is often reversible 
either spontaneously or with treatment. A variety of airway alterations occur in asthma, 
but airway inflammation is the final common pathway limiting airflow. Therefore steroid 
has been recognized as the basis of asthma therapy. 
 
Allergen and non-allergen (e.g. NSAID induced, exercise induced and cold 
induced) induce bronchoconstriction by triggering the release of mediators and 
metabolic products from inflammatory cells,  in particular T-helper cells that release 
cytokines such as interleukin (IL)-4, IL-5, and IL-13 (Kips JC,2001); eosinophils (Kay 
AB.,2005), lymphocytes (Larche et al., 2003), mast cells (Peter et al.,2006), 
macrophages (Peter et al.,2004), dendritic cells (Kuipers et al.,2004), and 
myofibroblast (Descalzi et al.,2007) which contribute to prolonged bronchial smooth 
muscle spasm (Hirst et al.,2004), edema, and mucus production (Chung et a.,2000).  
 
Airway remodeling refers to the persistent structural changes in airways seen in 
patients with asthma and is caused by the presence of repetitive or chronic airway 
inflammation. Microscopically the inflamed airways showed epithelial thickening, 
mucous gland metaplasia, subepithelial fibrosis, airway smooth muscles hypertrophy, 
loss of cartilage integrity, and angiogenesis. (Bergeron et al., 2010) Airway remodeling 
is observed in patients with prolonged asthma histories and their pulmonary function 
decline with age. Airway remodeling induced by chronic inflammation may lead to 
6 
 
development of chronic irreversible airflow. This group of patients has resistance to 
routine therapy and at risk of higher mortality. 
 
Acute exacerbation of bronchial asthma refers to transient worsening of 
respiratory effort characterized by expiratory airflow limitation as a result of exposure to 
trigger factors such as environment antigens (pollen, dander, mites) or microbiological 
antigens (bacteria, viruses).  
 
2.2 Diagnostic Strategies for Bronchial Asthma 
2.2.1  History Components 
 The diagnosis of asthma is based on the recognition of a characteristic pattern 
of symptoms and signs. Most patients with AEBA have a constellation of symptoms, 
including cough, dyspnoea, chest tightness, and wheezing (Levy et al., 2006) Clinical 
features that increase probability of asthma are: Diurnal variation in symptoms severity; 
Symptoms in response to exercise, allergen exposure, and cold air; Patient or family 
history of atopic disorder; Low peak expiratory flow rate (PEFR); Peripheral blood 
eosinophilia; History of improvement with treatment. 
 
 The brief history pertinent to current exacerbation should include onset and 
possible triggers, severity of symptoms especially as compare previous exacerbations, 
and other comorbidities. Drug history is another crucial component, including time and 
amounts of recent used asthma medication which indicate severity and controlled of 
asthma; any other potential drug that will exacerbate the symptoms of asthma. Risk 
factors for death from asthma are important to determine and are listed as below 
(National Asthma Education, 2007), which facilitate physician in decision for patient 
disposition. 
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Risk Factors for Death from Asthma    
Asthma History 
Previous severe exacerbation which required intensive care for asthma 
Two or more hospitalization for asthma in the past year 
Three or more visits to emergency department in the past year for AEBA 
Use of more than two MDI short acting β2-agonist canisters in past one month 
Hospitalization or visit to emergency department in the past month 
Difficulty perceiving asthma symptoms or severity of exacerbations 
Social History 
Lower social economy group or living in rural area 
Serious psychosocial problems 
Illicit drug use, e.g. inhaled cocaine and heroin (Levine et al., 2005) 
Comorbities 
Cardiovascular disease 
Other chronic lung disease 
Chronic psychiatric disease 
 
2.2.2 Physical Assessment 
 Patient with mild AEBA speak in sentence, those with moderate AEBA in 
phrases, and those with severe AEBA in words together with increase work of 
breathing. Cyanosis is uncommon in view of the left shift of the oxyhemoglobin 
dissociation curve produced by respiratory alkalosis. 
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Tachypnoea and tachycardia are associated with severe obstruction. The 
respiratory rate poorly correlate with PEFR and indicates severe obstruction if it is 
higher than 40 breaths per minute. 
 
 A pulsus paradoxus or inspiratory fall in systolic blood pressure greater that 
10mmHg usually signifies severe AEBA. However, its absent does not exclude severe 
disease 
.  
 Wheezing does not designate the presence, duration and severity of asthma. It 
correlates poorly with the degree of functional derangement and may be absent in life-
threatening condition. Physical assessment is crucial to identify signs from complication 
of asthma such as pneumothorax, pneumomediastinum or pneumonia. 
 
2.2.3 Test for Diagnosis and Monitoring of Bronchial Asthma 
 The severity of airflow obstruction cannot be accurately assessed from 
symptoms and physical examination alone (Silverman et al., 2007). Physician tends to 
underestimate the degree of airflow obstruction in acute asthma. Therefore 
measurements of lung function, and particularly the demonstration of reversibility of 
lung function abnormalities, greatly enhance diagnostic confidence. PEFR in litres per 
minute and force expiratory volume in 1 second from spirometry (FEV1) are available 
and gained widespread acceptance methods to assess airflow limitation in patients 
over 5 years of age. Predicted values of FEV1, FVC and PEFR based on age, sex and 
height have been obtained from population studies. (Nunn et al., 1989 and Radeos et 
al., 2004) An increase in of FEV1 ≥12% and 200ml after administration of 
bronchodilator agent specifies reversible airflow limitation which is consistent with 
diagnosis of asthma (Pellegrino et al., 2005). In peak expiratory flow measurement, 
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patient post administration of bronchodilatory agent show improvement of PEFR of 
60L.min or ≥ 20% of pre-bronchodilator PEFR suggests a diagnosis of bronchial 
asthma. (Dekker et al., 1992) Both measurements require the patient’s cooperation for 
maximal effort and are effort dependent. The best of three consecutive values should 
be recorded. Any patient unable to perform pulmonary function test should be 
considered to have severe airflow obstruction. 
 
 Spirometry is a preferable method in measuring lung function, because its result 
is reproducible, reliable but unfortunately it is effort dependent. Therefore most 
assessments in the emergency department use single-patient-use peak flow meter. 
Peak flow meter is relatively inexpensive, durable, portable and ideal for patient to use 
in home settings for day-to-day monitoring. The identical device should be used to 
assess then reassess an individual patient, and different meters should not be used 
interchangeably. Lastly, the FEV1 and PEFR measurements are not interchangeable in 
assessing acute airway obstruction. 
 
 Arterial blood gas is rarely clinically useful in AEBA unless oxygen saturation 
cannot be obtained reliably via pulse oximetry or saturation drop below 92%. Because 
neither pretreatment nor post-treatment arterial blood gases correlate with pulmonary 
function test or predict clinical outcomes. Occasionally, despite improvement in 
pulmonary function test values with bronchodilator therapy, some patients have 
transient fall in partial pressure of oxygen in arterial blood (Pao2) secondary to 
pulmonary vasodilatation and worsening ventilation-perfusion match.  
 
 The assessment of ventilation may be simplified nowadays, because there is a 
high concordance between end-tidal partial pressure of CO2 (Pco2) measured by 
10 
 
capnography and the Paco2 obtained with ABG measurement. (Corbo et al., 2005) 
Continuous monitoring patient’s response to bronchodilatory therapy in AEBA can now 
be easy and effortless using capnographic waveform analysis. (Nik Hisamuddin et al., 
2009)  
 
 Chest radiograph is of little value in most AEBA and should be restricted to 
patients with suspected complication from the primary disease such as pneumonia, 
pneumothorax, pneumomediastinum, congestive heart failure, life-threatening asthma 
with poor response to treatment, and patient who required mechanical ventilator 
support.   
 
2.2.3 Assessment of severity of AEBA in Emergency Department 
 A patient with acute exacerbation of bronchial asthma when presented to 
emergency department, assessment of the severity of exacerbation is crucial because 
it determines the types of treatment that need to be administered and the care facility 
level a patient needed in different severity. Most patient with severe to life threatening 
exacerbation need to be referred to hospital with acute intensive care facilities. Table 
below is adopted from GINA guideline 2012 which classify the severity of AEBA. 
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Table 1: Assessment of severity of AEBA 
 Mild Moderate Severe and life 
threatening 
Altered conscious level No No Yes 
Respiratory rate Increase Increase >30/min 
Talk in Sentences Phrases Words 
Pulses paradoxus Absent May be present Often present 
Wheezing intensity Moderate Loud Loud or silent 
chest 
Accessory muscles Absent Moderate Marked 
Pulse <100/min 100-120/min >120/min 
Initial PEFR >80% 60-80% <60% 
Oxygen saturation >95% 91-95% <90% 
 
2.3 Management of AEBA in Emergency Department 
2.3.1 Oxygen therapy 
 Oxygen supplement should be given to patient with saturation less than 90% 
(95% in pregnant and coexisting heart disease), titrated to maintain arterial oxygen 
between 94-98%.  
 
2.3.2 β2-agonist 
 Rapid acting inhaled β2-agonists either via nebulizers or holding chamber are 
the medication of choice use in AEBA for relief of bronchospasm e.g. salbutamol and 
terbutaline. (Cates et al., 2004)   Their use should be on an as-needed basis with the 
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lowest dose and frequency as possible. Increase daily use of β2-agonist is an indicator 
for poor asthma control. Similarly, failure of β2-agonist use to relief bronchospasm 
symptoms during AEBA warrants an emergency treatment and short term oral 
glucocorticosteroids. Inhaled β2-agonist has less side effects such as tremor and 
tachycardia than occur in oral β2-agonist. 
 
2.3.3 Glucocorticosteroids 
 Inhaled glucocorticosteroids are currently the most effective anti-inflammatory 
therapy for persistent bronchial asthma. Evidence has shown in their efficacy in 
reducing asthma mortality (Suissa et al., 2000), improving lung function test of patient, 
has better quality of life, reducing asthma symptoms (Juniper et al., 1990), reducing 
episodes of AEBA (Pauwels et al., 1997), and controlling airway inflammation. (Jeffery 
et al., 1992) 
  
 Systemic glucocorticosteroids are indicated for all moderate to severe AEBA or 
those experiencing incomplete response to initial β2-agonist therapy. The benefits of 
steroids include reduces the rate of relapse, speeds the resolution of airflow obstruction, 
and may decrease the hospital admission rate in severe AEBA. (Rowe et al., 2007) 
Steroid effects begin at 4-6 hours and peak at 24 hours. Oral glucocorticosteroid is 
favorable and is as effective as intravenous hydrocortisone. (Harrison et al., 1986)  
 
2.3.4 Anticholinergic Agents 
 Ipratropium bromide is one of the most commonly used anticholinergic drug in 
the treatment of AEBA. It has bronchodilator effect and reduces airway secretion. 
However, the maximum effect of inhaled ipratropium bromide is in 30 to 120 minutes 
and lasting up to 6 hours. In addition to this, its bronchodilating potency is lower and 
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onset of action slower than β2-agonists, therefore it should not be used alone in acute 
exacerbation of asthma. Clinical trial has shown that ipratropium bromide in 
combination with β2-agonists for severe AEBA modestly improve lung function test 
result and a reduction in hospitalization. (Rodrigo et al., 1999) 
 
2.3.5 Magnesium Sulfate (MgSO4) 
 Magnesium is the second most abundant intracellular cation in human body. 
Normal serum magnesium level is 1.5-2.5mEq/L. It plays a major roles in physiology 
function in the body, e.g. as cofactor of more than 100 enzymes in intracellular 
phosphorylation processes, DNA and protein synthesis, ATP function, 
neurotransmission, cardiac conduction and smooth muscle relaxation effect.  A 
research paper published in 1990, demonstrated a significant smooth muscle 
relaxation property of magnesium (Spivey et al, 1990). Another study proposed by 
(Lindeman et al, 1989) revealed that magnesium plays a role in airway smooth muscle 
relaxation by acting as a voltage-sensitive calcium channel blocker. In explanation, 
Cation Magnesium has a 2+ valence comparable to cation calcium. Consequently 
when MgSO4 is given as a therapy in acute asthma attack, magnesium acquires a 
competitive effect with calcium in the body which inhibit intake of calcium cation into 
smooth muscle cells in airway. Therefore airway smooth muscle relaxation occurred.  
 Magnesium relaxes bronchial smooth muscle and dilates asthmatic airway in 
vitro. Mechanism of actions include calcium channel blocking properties as mention 
above (Lindeman 1989), inhibition of cholinergic neuromuscular transmission (Del 
Castilo et al., 1954), stabilization of mast cells and T-lymphocyte (Bois, 1963), and 
increase β2-agonist bronchodilatory effect by enhancing the receptor affinity (Classen 
et al., 1987). 
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 Intravenous MgSO4 therapy in severe AEBA patient improves airflow limitation, 
prevent intubation and decrease hospital admission. (SIlverman et al., 2002) Side 
effects of magnesium infusion are dose related, toxicity occurred at serum magnesium 
level of 9mg/dL and above. However, 2g of intravenous magnesium bolus only 
increase the serum magnesium level from 2.2 to 2.8mg/dL 30 min after the infusion. 
(Elliott et al., 2009) Somehow it is still crucial to monitor for toxicity features such as 
warmth, flushing, sweating, nausea and vomiting, muscle weakness and loss of deep 
tendon reflex, hypotension and respiration distress. Magnesium nebulization still 
remains controversial even though a few publications supported for its efficacy use in 
adult and children with mild to moderate AEBA. (Blits et al., 2005 and Mahajan et al., 
2004 
2.4 Benefits of Nebulised MgSO4 in AEBA 
 Theoretically, Magnesium has shown bronchodilatory effect based on few 
published hypothesis. MgSO4 can induce bronchial smooth muscle relaxation by 
blocking the voltage-dependent calcium channels, subsequently it inhibits the uptake of 
calcium into cytosol of bronchial smooth muscle (Gourgoulianis et al., 2001). MgSO4 
can decrease the histamine release from the mast cells (Bois et al., 1963) and inhibit 
acetylcholine release from cholinergic nerve endings (Del custilo et al.,1954), in which 
both mechanism contribute to bronchial muscle relaxation. According to paper publishe 
in 1987 by Classen et al., magnesium has synergistic bronchodilator effect when given 
together with salbutamol. 
 There were two meta-analysis on the efficacy of nebulized MgSO4 published in 
two years apart showed contradict results. (Blitz et al., 2005 and Mohammed et al., 
2007) Among the 7 reviewed trials, only 3 trials with Jadad score of 5. Largest trial with 
total sample of 100 was from Aggrawal et al., 2006, showed no benefit of nebulized 
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MgSO4 in management of AEBA. A recent study by Gallegos et al., 2010 (n=60), 
showed improvement in lung function test, oxygen saturation and reduces admission 
rate at 90 minutes. Base on the reviewed trials, there were heterogeneity of MgSO4 
treatment dose, different severity of AEBA and small number of pooled studies, the 
experts have concluded that the evidence is still insufficient to recommend the use of 
nebulized MgSO4 in the treatment of AEBA. (Woo et al., 2012) 
Table 2: Summary of systemic reviews and meta-analysis on the efficacy 
of MgSO4 as an adjunct therapy for AEBA  
Study Sample size Outcome measure Results Conclusion 
Blits et al 
(2005) 
6 trials  
(296 patients) 
• Pulmonary 
function test 
• Admission to 
hospital  
• Pulmonary 
function test: 
SMD 0.30 (95% 
CI ,0.05 to 0.55) 
five studies 
• Admission to 
hospital: RR 0.67 
(95% CI,0.41 to 
1.09) four studies 
Benefit using 
MgSO4 as an 
adjuvant to β2-
agonists in 
AEBA 
Reduce 
hospital 
admission 
Mohammed 
et al (2007) 
7 trials 
(430 patients) 
• Pulmonary 
function test 
at 20min and 
60min 
• Admission 
rate 
• Pulmonary 
function test: 
SMD 0.17 (95% 
CI, 0.02 to 0.36, 
p=0.09) 
• Admission rate: 
RR 2.0 (95% 
CI,0.19 to 20.93, 
p=0.56) 
Poor evidence 
for MgSO4 to 
improve 
pulmonary 
function test 
Not significant 
to reduce 
admission rate 
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2.5 Methodological Quality of a Clinical Trail 
Randomized controlled trial has been recognized as the most powerful and 
revolutionary forms of research, which has contributed great importance in medical 
sciences advancement. (Jadad et al., 2007) Jadad scale/Jadad scoring or also known 
as Oxford quality scoring system has been described by a Columbian physician 
Alenjandro Jadad-Bechara. The purpose of this scoring was to standardize the quality 
of clinical trial. Jadad scoring was described as a three-point questionnaire, each 
question carried a single point if the answer is yes and zero point if the answer is no, 
the question as shown below. (Jadad et al., 1996) 
1. Was the study described as randomized? 
2. Was the study described as double blind? 
3. Was there a description of withdrawals and dropouts? 
To receive the corresponding point, an article should describe the number of 
withdrawals and dropouts, in each of the study groups, and the underlying reasons. 
Additional points were given if: 
• The method of randomisation was described in the paper, and that method was 
appropriate. 
• The method of blinding was described, and it was appropriate. 
Points would however be deducted if: 
• The method of randomisation was described, but was inappropriate. 
• The method of blinding was described, but was inappropriate. 
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3.0  HYPOTHESIS  AND  OBJECTIVES 
3.1  RESEARCH  HYPOTHESIS 
- Nebulized isotonic magnesium sulfate as an adjunct to salbutamol has 
significant mean difference of PEFR improvement  in the treatment of moderate 
AEBA in adults. 
3.2  OBJECTIVE 
3.2.1  General objective : 
- To determine the effectiveness of isotonic magnesium sulfate as an adjunct to 
nebulized salbutamol compare to salbutamol only group as a treatment in 
moderate AEBA in adults. 
3.2.2  Specific  objectives : 
- To compare the mean differences improvement of pulmonary function (PEFR) 
in this two groups of patient. 
- To compare the mean discharge time in this two groups of patient. 
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4.0  METHODOLOGY 
4.1  STUDY  DESIGN, SETTING  AND  DURATION  
This was a double-blinded, randomised control trial study with a goal to 
determine the mean difference improvement of PEFR in the treatment group and the 
control group with moderate AEBA. This study was conducted in Hospital Universiti 
Sains Malaysia (HUSM) for 12 months duration, from 1st October 2013 until 30th Sep 
2014.  This study consisted of 120 patients who presented with moderate AEBA. 
4.2  REFERENCE POPULATION  
Patients who presented with moderate AEBA as defined by GINA guideline 
2012 in Kelantan. 
4.3  SOURCE  POPULATION  AND  SAMPLING  FRAME  
Adult patients who presented to emergency department of HUSM in Kelantan 
with moderate AEBA. 
4.4  SAMPLE SIZE CALCULATION 
Calculation of sample size was based on data presented from the similar study 
by Nannini et al, 2000 in which to detect the difference in mean percentage 
improvement in PEFR between control and treatment group. 
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The sample size was calculated using the two proportion formula as below (Pocok’s 
formula):  
n = p1(1 - p1)  +  p2 (1 – p2)  x   (zα + zβ)2 
      ____________________ 
                   (p1 – p2)2 
 
P1 = 0.61 Percentage increase in PEFR of treatment groups from literature review 
(Nannini et al., 2000) 
P2 = 0.31 Percentage increase in PEFR of control groups from literature review 
(Nannini et al., 2000) 
Zα  = 1.96 for α = 0.05 (two-tailed) 
Zβ  = 1.28 for 90% power  
n = 56 with PS software 
n = 67 in each arm with added 20% drop out. 
 
4.5  INCLUSION AND EXCLUSION CRITERIAS  
Patients with the below criteria were included into the study: 
 
1) Patient with history of bronchial asthma 
2) Fulfil the criteria for moderate exacerbation as defined by GINA 
guideline 2012. Characters of moderate AEBA include increase 
respiratory rate but not altered in conscious level, talking in phrases, 
moderate usage of accessary muscles, pulserate of 100 - 120bpm, loud 
wheezing, oxygen saturation between 91% to 95%, may be present of 
pulses paradoxus, initial PEFR between 60% to 80% of predicted value. 
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The present of several characters, but not necessaryly all indicates the 
classification of exacerbation. 
3) Age between 18 – 65 years old 
4) Consented patient 
5) First visit for current exacerbation who has not been enrolled in study 
 
However, those with any of the below criteria were excluded: 
 
1) Age < 18 or > 65 years old 
2) High grade fever with suspected pneumonia 
3) Chronic obstructive pulmonary disease 
4) Cardiac arrythmias 
5) Heart failure 
6) Chronic kidney disease 
7) Pregnancy 
8) First presentation with wheezing 
9) Patient who deteriorated during the trial 
 
4.6  ETHICS AND CONSENT 
This study was approved by the Health and Human Medical Research and 
Ethics Committee of USM in 26th September 2013. Written consents were obtained 
from patients after they fulfilled the inclusion and exclusion criteria. 
4.7  SAMPLING METHOD 
All patients who presented to emergency department of HUSM with moderate 
AEBA were triaged to asthma bay. Brief history taking, physical examination and PEFR 
were performed on patient involved. Patients who had symptoms with medical history 
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of asthma as mentioned in GINA 2012 were selected as research candidates. 
Candidates who fulfill the inclusion and exclusion criterias and consented were 
recruited into the study. 
 
4.8  STUDY METHOD  
Each patient presented to emergency department of HUSM with AEBA was 
evaluated in the primary and secondary triage counter. Patient fulfilled the criterias for 
severe AEBA (GINA, 2012) was sent to critical care area. However, patients with mild 
to moderate asthma were triaged to asthma bay for further assessment and treatment. 
Each patient was evaluated using a simple clerking sheet. Pulse, blood pressure, 
oxygen saturation, respiratory rate, and pre-nebulization PEFR were recorded. Patient 
who fulfilled the criteias for moderate AEBA was selected as our study population. 
Finally, only patient who fulfilled the inclusion criteria and consented was selected as 
research candidate. Patient who was exluded was given AEBA standard treatment as 
per protocol. 
Patients who were recruited into our study were randomly allocated into two 
groups. Best of three readings of Pre-bronchodilator PEFR was recorded at 0 minute 
using a mini Wright’s (standard range) peak flow meter ( Clement Clerk International, 
United Kingdom). Patient subsequently recieved medication via nebulization using a jet 
nebulizer. The research medication was prepared by pharmacist in HUSM. We use 
block randaomization, which will be explained in the later part. Post treatment,  pulse, 
blood pressure, oxygen saturation, respiratory rate, and post-bronchodilator PEFR 
were again recorded at 20 minutes.  
 
22 
 
 
4.8.1 Randomization and research medication preparation method: 
Block randomization was choosen, total of 20 blocks were prepared by 
pharmacist in HUSM. Each block contained 6 syringes with equal number of treament 
A and B at any time of study. When study subjects were recruited, the treatment in the 
block were allocated. The content in the sryinges were blinded to the researcher and 
patient during the sampling period. The list of content in syringes were reviewed to the 
reseacher only after completed the study.  
Patients who were recruited into the study were randomly allocated into two 
types of medication group as describe below: 
1. Group A – 3 mls of 0.9% normal saline 
2. Group B – 3 mls of prepared MgSO4 isotonic solution (7.5g or 3 ampules of 
MgSO4 were mixed into 100mls of 0.9% normal saline) 
At 0 minute, patients were allocated in one of the two groups stated above, 1 ml 
of salbutamol solution (5mg) were added in the nebulizer chamber in both groups. The 
drugs were delivered using jet nebulizer over a period of 5 to 8 minutes. At 20 minutes 
post treatment, pulse, blood pressure, oxygen saturation, respiratory rate, and post-
bronchodilator PEFR were recorded. Patients’ condition were reassesed at 20 minutes 
post treatment, standard AEBA treatment was continued as per protocol. Patients were 
allow to discharge home if their PEFR achieved >80% of predicted PEFR value for 
age, sex and height. Time from treatment initiated until patient discahged was 
recorded. 
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4.8.2 Data collection 
 Primary objective for this study was to determine the mean difference of PEFR 
improvement in this two study groups describe as absolute percentage improvement of 
PEFR post treatment (post nebulization PEFR minus pre nebulization PEFR divided by 
expected/best PEFR then multipled by 100). 
 Secondary objective for this study was to compare the means treament duration 
for this two groups, it is recorded as total minutes needed for treatment. 
 
4.9  STATISTICAL ANALYSIS 
All the data collected were entered and analyzed using SPSS version 22.0 
licenced to HUSM. Descriptive statistic of the variables was calculated and presented. 
The mean and standard deviations for numerical variables and frequency and 
proportion for categorical variables were reported along with histogram, pie chart or bar 
chart.  
For univariable analysis, the mean difference of improvement in PEFR 
described as percentage in PEFR from the baseline were analysed using a parametric 
independent t-tests. P value of ≤ 0.05 was considered to indicate statistical significance, 
two tailed. The mean changes of PEFR before and after treatment of each group and 
means difference of vital signs of each group was analysed using paired t-test, with 
statistically significance set at p value ≤ 0.05, two-tailed. Pearson’s correlation was 
used to determine the relation between pre-nebulization PEFR and outcome PEFR in 
two study groups. P value of <0.05 was considered statistically significant. 
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4.10  FLOW CHART OF STUDY 
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